Arbutus Biopharma Corporation (NASDAQ: ABUS) has announced new data from its im-Prove I Phase 2a clinical trial (AB-729-201) showing significant progress in achieving a functional cure for patients ...
Plexus Corp. attributed the decrease in net sales to market-driven inventory corrections and weaker customer demand, particularly in the Healthcare/Life Sciences and Industrial market sectors. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback